M., Hay, D
Interestingly, a Phase IIa open-label, randomized controlled trial with the registration number NCT01490996 confirmed that patients receiving folic acid/5-fluorouracil/oxaliplatin chemotherapy (FOLFOX) had a Hazard Ratio (HR) for overall survival (OS) of 0.34 (P = 0.02) when compared to the FOLFOX + 2 grams of oral curcumin/d (CUFOX)
Oncotarget 11 , 13991416 (2020)
Promotional Practices and Advertising Scrutiny In addition to productliability claims and compounding enforcement, promotional practices are a growing source of legal and regulatory exposure in the GLP1 space, especially as these therapies remain highvisibility and are frequently marketed through telehealth, subscription programs, and directtoconsumer channels
You may feel a slight sting from the injection, but this should subside quickly
Serious adverse effects are rare but can include severe allergic reactions or exacerbation of existing health conditions